$7.76
+0.30 (+4.02%)
Open$7.49
Previous Close$7.46
Day High$7.82
Day Low$7.49
52W High$8.41
52W Low$3.72
Volume—
Avg Volume641.2K
Market Cap52.63M
P/E Ratio58.53
EPS$0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3.5% upside
Current
$7.76
$7.76
Target
$8.03
$8.03
$5.28
$8.03 avg
$9.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.19M | 11.47M | 10.10M |
| Net Income | 876.0K | 905.7K | 740.1K |
| Profit Margin | 7.2% | 7.9% | 7.3% |
| EBITDA | 1.90M | 1.88M | 1.67M |
| Free Cash Flow | 486.5K | 519.3K | 559.1K |
| Rev Growth | +7.7% | +14.6% | +19.0% |
| Debt/Equity | 1.27 | 1.35 | 1.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |